Business, energy, technology, markets and global industry news from Business News Today

Mounjaro

Pharma & Biotech

Can low doses of Ozempic, Wegovy, Mounjaro and Zepbound still cause weight loss?

A new real-world study of sustained low-dose semaglutide and tirzepatide found measurable weight loss without escalation to standard maintenance doses, but researchers stress that prescription records do not prove intentional GLP-1 microdosing and the observational findings cannot establish cause and effect.

Read More
Pharma & Biotech

Mounjaro is no longer just about blood sugar and weight. FDA approval pushes Lilly into a bigger cardiovascular fight

The FDA has approved Eli Lilly and Company’s Mounjaro to reduce cardiovascular death, heart attack and stroke risk in high-risk adults with type 2 diabetes, significantly broadening the clinical case for tirzepatide beyond glucose control and weight reduction.

Read More
Pharma & Biotech

Can Eli Lilly’s Foundayo and retatrutide deepen its grip on the diabetes and obesity market?

Find out how Eli Lilly’s Foundayo and retatrutide data could reshape diabetes, obesity and cardiometabolic care.

Read More